menu

CME: Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events

Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
RestartResume
Join Drs. Bhatt and Gibson as they review new data that could lead to a new paradigm for reducing thrombotic risk.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This CME activity is based on a live symposium held on April 26, 2018. It features a 15-minute Video Expert Dialogue with two internationally renowned faculty evaluating clinical issues and recent data regarding anticoagulation in patients with coronary artery disease (CAD). 

  • Provider(s)/Educational Partner(s)

    Jointly provided by the Annenberg Center for Health Sciences at Eisenhower (www.annenberg.net) and Medtelligence in collaboration with Postgraduate Institute for Medicine.

    This activity is supported by an independent medical educational grant from Janssen Scientific Affairs, LLC.

  • Target Audience

    This activity has been designed to meet the educational needs of Interventional/Invasive Cardiologists, Cardiologists, Fellows, and other Healthcare Professionals involved in the care of patients with coronary artery disease.

  • Educational Objectives

    After completing this activity, the participant should be better able to:

    • Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
    • Relate the clinical implications of anticoagulation in CAD, based on recent data
  • Faculty

    Deepak L. Bhatt, MD, FSCAI, Chair
    Executive Director, Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor, Harvard Medical School
    Boston, MA

    C. Michael Gibson, MD, FSCAI
    Professor of Medicine, Harvard Medical School
    CEO and President, Baim Institute and PERFUSE Study Group
    Founder, Editor-in-Chief, Wikidoc.org
    Boston, MA

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

    • Dr. Bhatt: Contracted Research: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company.
    • Dr. Gibson: Research/Grant Funding: Angel Medical, Bayer, CSL Behring, Janssen, Johnson & Johnson, Portola: Peer to Peer Communications: The Medicines Company; Consultant: Amarin, Amgen, Bayer, Boston Clinical Research Institute, Cardiovascular Research Foundation, Eli Lilly, Gilead, Janssen, Johnson & Johnson, The Medicines Company, Novo Nordisk, Ortho McNeil, Pfizer, Pharma Mar, Roche, St. Francis Hospital, St. Jude Medical, Web MD; Royalties: UpToDate in Cardiovascular Medicine.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The PIM planners and managers have nothing to report.

    Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower, both have no relevant commercial relationships to disclose.

    The Medtelligence planners and managers, Ben Caref, PhD, and Pamela Clark, have nothing to disclose.

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period June 26, 2018 through June 26, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity and evaluation will have a statement of credit made available immediately.

    If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.